Cardiovascular Disease

Access to Healthcare

Prioritizing the needs of patients

Access to HealthcareCardiovascular DiseaseHeart DiseaseNovartis Access
Access to Healthcare

Expanding a new digital healthcare solution across chronic heart disease management

More than 100,000 patients with heart failure in China are using our new AI-enabled platform, AI Nurse, to manage their condition and aim for better health.

DigitalReimagine MedicineCardiovascular DiseaseFuture of HealthcareAccess to Healthcare
Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol

Reimagine MedicineInnovationCardiovascular DiseaseAd Hoc
Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy

Basel, March 18, 2020 — Novartis announced today the publication of three pivotal Phase III clinical trials for inclisiran, a potential first-in-class small interfering RNA (siRNA) investigational agent for hyperlipidemia in adults. The findings were published in two online articles ahead of print in The New England Journal of Medicine. The…

Reimagine MedicineHeart DiseaseCardiovascular Disease
Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment

Basel, March 28, 2020 — Novartis today announced results from a prespecified analysis of pooled data from three Phase III studies evaluating the safety and efficacy of inclisiran, its first-in-class investigational treatment for hyperlipidemia in adults. The data was presented during a Late Breaker session at the American College of Cardiology’s…

Reimagine MedicineInnovationCardiovascular Disease